Valeant Pharmaceuticals Completes $365 Million Rule 144A Offering
Date: 06/09/09
Cahill represented UBS Securities LLC and the other initial purchasers in the $365,000,000 Rule 144A Offering by Valeant Pharmaceuticals International of its 8.375% Senior Notes due 2016. The proceeds will be used for general corporate purposes, which may include funding securities repurchases.